<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01941953</url>
  </required_header>
  <id_info>
    <org_study_id>NP 273/12</org_study_id>
    <nct_id>NCT01941953</nct_id>
  </id_info>
  <brief_title>Metformin and 5-fluorouracil for Refractory Colorectal Cancer.</brief_title>
  <official_title>Phase II Study of Metformin and 5-fluorouracil in Patients With Advanced Colorectal Cancer Previously Treated With Oxaliplatin and Irinotecan Based Chemotherapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto do Cancer do Estado de São Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto do Cancer do Estado de São Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase II trial to evaluate efficacy and safety of Metformin and Fluorouracil in&#xD;
      patients with metastatic colorectal cancer (CRC) who have progressed after Oxaliplatin and&#xD;
      Irinotecan based chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Outcomes Measures:&#xD;
&#xD;
      - Disease control Rate at 8 weeks according to RECIST 1.1 (Tumor response was defined as the&#xD;
      percentage of patients with complete response, partial response or stable disease as best&#xD;
      overall response).&#xD;
&#xD;
      Secondary Outcome Measures:&#xD;
&#xD;
        -  Progression-free Survival&#xD;
&#xD;
        -  Overall Survival&#xD;
&#xD;
        -  Adverse Events (assessed according to the Common Toxicity Criteria for Adverse Events&#xD;
           (CTCAE) version 4.0)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Control Rate according to RECIST 1.1</measure>
    <time_frame>From randomization of the first subject until the database cut-off approximately 12 months later (01Nov2012 up to 01Nov2015). Tumor assessed at 8 week intervals</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>From randomization of the first subject until the database cut-off approximately 12 months later (01Nov2012 up to 01Nov2015). Tumor assessed at 4 week intervals.</time_frame>
    <description>defined as time from randomization to death from any cause, or even radiological detection/or clinical of disease progression, increased CEA will not be considered isolated progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From randomization of the first subject until the database cut-off approximately 12 months later (01Nov2012 up to 01Nov2015). Tumor assessed at 4 week intervals</time_frame>
    <description>defined as time from first dose of treatment until death, with date of last visit being considered censorship</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From randomization of the first subject until the database cut-off approximately 12 months later (01Nov2012 up to 01Nov2015). Tumor assessed at 4 week intervals.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Metformin and Flourouracil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin and Fluorouracil</intervention_name>
    <description>metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly</description>
    <arm_group_label>Metformin and Flourouracil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Histological diagnosis of metastatic colorectal adenocarcioma previously treated with&#xD;
             at least two lines of chemotherapy (oxaliplatin and irinotecan regimens) if mutated&#xD;
             KRAS or treated with at least 3 lines of chemotherapy (oxaliplatin, irinotecan and&#xD;
             cetuximab) if KRAS wild type.&#xD;
&#xD;
          -  Disease progression according to radiological or clinical assessment.&#xD;
&#xD;
          -  Measurable disease.&#xD;
&#xD;
          -  ECOG Performance 0-1.&#xD;
&#xD;
          -  Age above 16 years.&#xD;
&#xD;
          -  Normal organic function as defined for the following criteria:&#xD;
&#xD;
               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 times the&#xD;
                  upper normal limit of the local laboratory (LSN-LL);&#xD;
&#xD;
               -  Total serum bilirubin ≤ 2.0 x ULN-LL;&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1,500 / mm3;&#xD;
&#xD;
               -  Platelet count ≥ 100,000 / mm3;&#xD;
&#xD;
               -  Hemoglobin ≥ 8.0 g / dl;&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN-LL&#xD;
&#xD;
          -  Written informed consent before enrollment&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Diabetic patients taking metformin.&#xD;
&#xD;
          -  Patients already treated with mTOR inhibitors.&#xD;
&#xD;
          -  Hypersensitivity to metformin, renal or hepatic impairment or other conditions that&#xD;
             predispose to lactic acidosis.&#xD;
&#xD;
          -  History of acute myocardial infarction in the last 6 months&#xD;
&#xD;
          -  Serious illness or psychiatric condition.&#xD;
&#xD;
          -  Current participation in other protocols with experimental drugs.&#xD;
&#xD;
          -  Suspicion of dihidropirimida dehydrogenase(DPD)deficiency.&#xD;
&#xD;
          -  Presence of active infection.&#xD;
&#xD;
          -  No ability to ingest food orally.&#xD;
&#xD;
          -  Patients with metastatic disease to CNS.&#xD;
&#xD;
          -  Patients who underwent major surgery in the last 4 weeks.&#xD;
&#xD;
          -  Patients who received chemotherapy in the last three weeks.&#xD;
&#xD;
          -  Patients who underwent radiotherapy in the last 2 weeks or who received radiotherapy&#xD;
             in the target lesion, if this is the only target lesion.&#xD;
&#xD;
          -  Patients using oral anticoagulation (warfarin).&#xD;
&#xD;
          -  Pregnant or lactating patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Instituto Do Cancer Do Estado de São Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01246-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>September 4, 2013</study_first_submitted>
  <study_first_submitted_qc>September 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2013</study_first_posted>
  <last_update_submitted>April 6, 2015</last_update_submitted>
  <last_update_submitted_qc>April 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto do Cancer do Estado de São Paulo</investigator_affiliation>
    <investigator_full_name>Vanessa C Miranda</investigator_full_name>
    <investigator_title>Fellow in Clinical Oncology</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Metastatic Colorectal Cancer</keyword>
  <keyword>Fluorouracil</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

